【摘要】 目的 :研究抗人血管内皮生长因子 (VEGF)单抗E1 1 抑制移植性人颊鳞癌血管生成 ,从而抑制颊癌生长的作用效果。方法 :接种人颊鳞癌BCaCD885细胞株的BALB c裸小鼠分别通过腹腔或瘤周皮下注射抗人VEGF单抗或生理盐水。每隔 3d测量瘤体积 1次 ,接种后第 18天处死裸鼠并称取瘤重 ,计算抑瘤率。结果 :①不同给药途径的抗人VEGF单抗对颊癌的生长均有明显的抑制作用 ,与生理盐水组相比较有显著性差异 ,其抑瘤率分别为 6 0 1%、6 9 9%。②腹腔、瘤周皮下两种注射方式比较 ,瘤周皮下组的抑瘤效果更为显著。结论 :肿瘤中的VEGF是抗肿瘤血管生成的理想靶目标 ,而抗人VEGF单抗又是该抑癌新途径的理想选择 ,具有潜在的重要临床应用价值更多还原

【Abstract】 Objective:The purpose of this study was to apply the anti_human VEGF monoclonal antibody E\-\{11\}, which was generated against a synthetic peptide from the NH\-2 of the human VEGF （residues 1₂6）, to against VEGF in buccal carcinoma, and to examine the inhibition effect of the antibody on the carcinoma growth. Methods:E\-\{11\} was hypodermic and celiac injected, with 200 μg each from the first to the 15th day, into BALB/c nu/nu mice, which were transplanted with human buccal carcinoma. The saline was injected as the negative control. Mice were killed on the 18th day. The tumor weight was determined and the inhibition rate was calculated. Results:The growth of BCaCD885 carcinoma was dramatically inhibited in the E\-\{11\} group. There was a significant difference in tumor weight between the saline group and the E\-\{11\} groups during the observation period. The tumor growth inhibition rate in the mice hypodermically injected with E\-\{11\} reached 69.9%. Conclusion:The anti_human VEGF monoclonal antibody E\-\{11\} significantly inhibits tumor growth by blocking the action of VEGF, and without obvious side effects, therefore the anti_human VEGF monoclonal antibody could be applied clinically in the anti_angiogenic treatment of solid tumors.\;更多还原